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Abstract
Background: The present study analyses the ability of the alveolar slope of the single-breath nitrogen washout
test (N2-slope) to diagnose and predict the development of the bronchiolitis obliterans syndrome (BOS).
Methods: We present a retrospective analysis of 61 consecutive bilateral lung or heart-lung transplant recipients
who were followed at regular control visits during a three year follow-up. The operating characteristics of the N2-
slope to diagnose BOS and potential BOS (BOS 0-p) and to predict BOS were determined based on cut off values
of 95% specificity.
Results: The sensitivity of the N2-slope to identify BOS was 96%, and BOS 0-p 100%. The predictive ability to
predict BOS with a N2-slope > 478% of the predicted normal was 56%, and if combined with a coincident FEV1 <
90% of the basal value, the predictive ability was 75%.
Conclusions: The predictive ability of either the N2-slope or of FEV1 to diagnose BOS is limited but the
combination of the two appears useful. Follow-up protocols of bilateral lung and heart-lung transplant recipients
should consider including tests sensitive to obstruction of the peripheral airways.
Background
Bronchiolitis obliterans is the leading cause limiting
long-term survival after lung transplantation [1]. The
prevalence is 50 to 60% in long-term survivors and
account for 30% of all deaths after the third postopera-
tive year [2]. The pathogenesis and pathophysiology are
not fully known and the effect of treatment regimens
has been disappointing. During recent years new treat-
ments have been attempted but the effect on long term
survival has so far been limited [3,4]. It is likely that an
early diagnosis is potentially favourable by leading to
earlier initiation of therapy and possibly an improved
prognosis.
A histologic diagnosis of bronchiolitis obliterans is
usually not obtained due to the insensitivity of trans-
bronchial biopsies [5]. The term bronchiolitis obliterans
syndrome (BOS) was therefore introduced and based on
a ≥ 20% decrease in FEV1 rather than on histology [6].
BOS stage 0-p was put forward by Estenne et al in an
update of the original staging system in order to identify
potential BOS patients and was defined by a decrease in
FEV1 between 10% to 19% from the baseline value [7].
The stage BOS 0-p, based on the FEV1 criterion, has
since been reported to be “a reasonable predictor of
BOS stage 1 after bilateral lung transplantation” [8].
In a preliminary report in 1997 [9], we showed that
uneven intrapulmonary ventilation distribution, as indi-
cated by an increased alveolar slope of the single-breath
nitrogen test (N2-slope) [10], seemed to precede the
decline of FEV1 in BOS patients. This finding has since
been confirmed by Reynaud-Gaubert et al [11] who
reported a high sensitivity but low specificity of the N2-
slope to diagnose BOS. Estenne et al [12] measured the
alveolar nitrogen and helium slopes following inhalation
of one litre of a gas mixture containing helium and
reported that raised slopes preceded the development of
BOS, but the associated specificities were rather low.
The sensitivity of a test is defined by the chosen thresh-
old value and a high sensitivity may be obtained on the
expense of a low specificity. Therefore, these sensitivities
are difficult to compare and interpret.
The ability of a lung function test to diagnose a dis-
ease is usually based on its lower limit of normal, gener-
ally defined as the 5
th or 95
th percentile of values in a
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recipients, “normal values” are almost certainly different
from a healthy population, and the lower limit normal
should preferably be defined by the 5
th or 95
th percentile
of transplanted patients without known graft
complications.
The aims of the present analysis was first to analyse
the operating characteristics of the N2-slope to diagnose
BOS and BOS 0-p by applying a cut off value chosen to
give a specificity of 95%, and secondly to analyse the
ability of the N2-slope to predict the development of
BOS.
Methods
A total of 92 patients underwent heart-lung or bilateral
lung transplantation between January 1990 and April
2003 in the Gothenburg Lung Transplantation Program.
The study design was approved by the Ethical Committe
of the University of Gothenburg (Dnr. 044-05).
The present study is a retrospective analysis of the 61
patients available at a two year follow-up examination. 31
patients were not included (21 had died, 9 were incapaci-
tated due to post-transplant co-morbidity and 1 patient
was unable to reach). Fifty-two patients took part in a
three year follow-up examination. Out of the included 61
patients, 24 patients were heart-lung transplanted and 37
patients had undergone bilateral lung transplantation, 33
were women and 28 men. Their mean age was 34 years
(range 7 - 58). The preoperative diagnoses were primary
pulmonary arterial hypertension (n = 17), Eisenmengers
syndrome (n = 17), cystic fibrosis (n = 11), chronic
obstructive pulmonary disease or alfa-1-antitrypsin defi-
ciency (n = 4), idiopathic pulmonary fibrosis (n = 2), and
various other diagnoses (n = 10).
During the follow up period, all patients received a
standard immunosuppressive protocol of cyclosporine,
azathioprine and steroids. Regular visits at the transplant
unit including clinical, radiological and pulmonary func-
tion examinations, bronchoscopy with bronchoalveolar
lavage and transbronchial biopsies took place 1, 2, 3,
4.5, 6, 9, 12, 18, 24 and 36 months post transplantation.
A detailed account of the follow-up regimen has earlier
been published [13].
Pulmonary function tests were performed by experi-
enced and skilled technicians in a specialized respiratory
laboratory. The quality control and performance of
spirometry, measurements of lung volumes and carbon
monoxide uptake (CO-uptake), i.e. transfer factor or dif-
fusing capacity, were in accordance with the European
recommendations [14,15]. Spirometry was performed on
a rolling seal spirometer (SensorMedics 922, SensorMe-
dics Co., Yorba Linda, CA, USA). Volume calibration
was checked daily. In almost all instances three accepta-
ble recordings were obtained. The forced expiratory
vital capacity (FVC) and FEV1 were taken as the largest
from the acceptable recordings. Lung volumes, i.e. total
lung capacity (TLC), functional residual capacity (FRC)
and residual volume (RV) were obtained in a body
plethysmograph (SensorMedics 2800, SensorMedics Co.,
Yorba Linda, CA, USA). Volume and pressure calibra-
tions were checked before each measurement and the
panting frequency was kept below 1 Hz. CO-uptake was
obtained by the single-breath method using standard
equipment (SensorMedics 2200, Sensor Medics Co.,
Yorba Linda, CA, USA). Volume and gas concentration
calibrations were checked daily.
The N2-slope was determined by a homemade bag in
box system [16] using a rapid nitrogen analyzer (Med.
Science Nitralazer 505). The N2-slope was determined
by a defined algorithm [16,17] with minimal possibilities
for subjective influence. Volume and nitrogen calibra-
tions were checked at each investigation and the tra-
cings were read by a laboratory physician without
knowledge of the status of the patient. Two acceptable
recordings were obtained in almost all instances and the
average value used for further analysis.
Predicted normal values for spirometry and lung
volumes are according to Quanjer et al [15], CO-uptake
according to Salorinne [18], and the N2-slope according
to Sixt et al [19].
BOS and BOS 0-p were diagnosed according to the
2001 update of the diagnostic criteria [7] but without
considering FEF25-75 as it was not measured at the time.
Baseline values were calculated for all variables and
based on test results as from 4.5 months after transplan-
tation. Test results obtained at the various instances
were then expressed as a percentage of the latest base-
line value, similarly as for FEV1. Calculations of cut off
values were based on all test results between 6 and 36
months of the 43 stable patients and were chosen to
result in 95% specificity.
The ability of the N2-slope to predict BOS was deter-
mined by the ratio of abnormal results (i.e. outside the
cut off value) preceding the diagnosis of BOS and the
sum of all abnormal test results among patients without
BOS. Expressing this ratio as a percentage signifies the
probability of an abnormal result to be associated with
the development of BOS within the follow up period.
Results as from 6 months post transplantation were
considered in the analysis. Three patients were excluded
in this analysis and in the analysis of operation charac-
teristics as they were diagnosed with BOS 0-p at the
final visit and consequently the relation to BOS is
unclear. Of note is that the calculation of the prognostic
ability is principally different from the conventional cal-
culation of a positive predictive value in that it specifi-
cally considers results preceding BOS and not results
when patients have been diagnosed with BOS.
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nificant differences between the patients who developed
BOS and those who did not. Standard software packages
(Statistica 7; StatSoft, Inc . ,T u l s a ,O K ,U S A )a n dE x c e l
(Microsoft Inc., USA) software were used.
Results
Spirometry was obtained at 470 occasions, lung volumes
at 406, CO-uptake at 424, and N2-slope at 363 occa-
sions. Six patients died during the follow up period. The
prevalences of BOS and BOS 0-p at the various time
points are shown in table 1.
Table 2 presents median values of relevant pulmonary
function variables obtained 6 and 36 months after trans-
plantation. Six months after transplantation the CO-
uptake was substantially reduced and the N2-slope
abnormally increased, but there were no significant dif-
ferences between NoBOS and BOS patients. Thirty-six
months post transplantation the NoBOS patients
remained essentially unchanged whereas among BOS
patients FEV1,F V C ,R Va n dN 2-slope had deteriorated
and were significantly different from the NoBOS patients.
Table 3 shows the prevalence of normal and abnormal
test results and 3b the resulting operating characteris-
tics. Thus, the sensitivity to diagnose BOS and BOS 0-p
of the N2-slope in percent predicted normal was almost
as high as for FEV1 < 90% of the basal value (96% versus
100%, table 4). The corresponding positive predictive
values were also similar but much lower. The results
regarding TLC, FRC, RV and CO-uptake are not shown
as the sensitivities were very low.
BOS 0-p preceded BOS in 4 of the 15 BOS patients,
giving a sensitivity of 27%. There were 46 patients who
did not develop BOS during the follow up period and
43 of these were not diagnosed as BOS 0-p resulting in
specificity of 93%. There were three subjects diagnosed
as BOS 0-p where the development of BOS was uncer-
tain and thus the positive predictive value may be con-
sidered to be 57%.
The ability of a single test result to predict BOS was
determined regarding FEV1 < 90% of the basal value,
and regarding the N2-slope > 478% of the predicted nor-
mal value. Table 5 shows that if a FEV1 result is < 90%
of the basal value, the probability of that result to pre-
cede BOS is 31% whereas the corresponding probability
for the N2-slope > 478% of predicted normal is 56%.
Furthermore, both tests were “abnormal” simultaneously
at 12 instances and 9 of these preceded BOS. Conse-
quently, there is a 75% probability that this combination
predicts the development of BOS. Figure 1 illustrates
t h ep r e v a l e n c eo v e rt i m eo fb o t ht e s tr e s u l t ss i m u l t a -
neously being abnormal. The predictive ability does not
appear to change systematically over time.
Discussion
The present study shows that an abnormal N2-slope in
combination with a FEV1 result < 90% of the basal
value, predicts the development of BOS with a probabil-
ity of 75%. Using either FEV1 or the N2-slope by them-
selves were not as useful. The single-breath N2-slope
identified BOS and BOS 0-p in almost all cases, but
since there were abnormal values among patients with-
o u tB O Sa n dB O S0 - pt h ep o s i t i v ep r e d i c t i v ev a l u e s
were lower.
The BOS 0-p stage, i.e.a na v e r a g ed e c l i n ei nF E V 1 of
10-19% of the basal value of two measurements at least 3
weeks apart, was added in 2002 to the BOS scoring sys-
tem in an attempt of early detection of bronchiolitis
obliterans [7]. Hachem et al reported a positive predictive
v a l u eo fB O S0 - po f7 9 %b a s e do na na n a l y s i so f1 8 3
bilateral recipients including 72 BOS 0-p patients [8].
Our results indicate that the positive predictive value of
diagnosed BOS 0-p is only 57%, but this value is based
on a lower patient number and on the assumption that
three patients who were diagnosed as BOS 0-p at the
very last control visit did not develop BOS. If only one of
these three BOS 0-p patients in fact did develop BOS, the
positive predictive value would have been 71%.
Measurements of ventilation distribution by single-
breath washouts for N2, helium, and sulfur hexafluoride
Table 1 Number of patients divided according to the BOS
stage at the regular control visits during the 3 years
follow up of 61 double lung recipients
Months after transplantation
6 9 12 18 24 36
NoBOS 61 57 52 50 49 43
B O S 0 - p 013223
B O S 1034413
B O S 2000111
B O S 3002481 1
Table 2 Median values of lung function results expressed
in percent of the predicted normal value
Lung function variable 6 months post
transpl.
36 months post
transpl.
NoBOS BOS NoBOS BOS p value*
FEV1 83 74 88 44 < 0,001
FVC 76 76 89 64 < 0,001
RV 108 93 89 132 0,011
TLC 87 78 91 89 0,505
CO uptake 52 56 61 53 0,256
N2-slope 189 170 211 950 < 0,001
P-values refer to differences between NoBOS and BOS 36 months post
transplantation
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ventilation measures in the detection of ventilation dis-
turbances in the peripheral airways in smokers, asthma,
and cystic fibrosis [16,20,21]. Especially the slope of the
single-breath N2 test proved highly sensitive in the
detection of early disturbances of ventilation in the per-
ipheral airways caused by tobacco smoke [16]. In that
study, based on 97.5% specificity, 58% of 50 years old
male heavy smokers (> 15 g/d) had abnormally steep N2
slope whereas only 28% had abnormal FEV1. Thus,
there is comprehensive amount of evidence showing
that single breath wash out tests are useful in early
detection of abnormalities in peripheral airways.
A recent study by Van Muylem et al [22] showed that
the helium slope of the single-breath washout was more
sensitive in detecting BOS stage 0-p than exhaled bio-
markers, i.e. NO and CO. Other authors have analysed
the usefulness of the single-breath N2 slope to diagnose
BOS. Reynaud-Gaubert et al [11] used the single-breath
N2 slope similarly as in the present study and reported a
sensitivity of 100% in the detection of BOS in 47
patients after heart-lung or double lung transplantation.
In that study, however, the chosen cut off value of 3%
N2/L obtained at least twice, was acquired in 6 out of
25 patients without BOS resulting in a positive predic-
tive value of 78.5%. Estenne et al measured the slope of
the alveolar plateau of various gases following inhalation
of 1 L of a gas mixture of helium and sulfur hexaflour-
ide and also found a very high sensitivity. The associated
cut off values were defined by the confidence interval
obtained in 10 stable lung transplant recipients, result-
ing in a specificity of 82% [12].
As any sensitivity may be achieved by choosing var-
ious cut off values, it is desirable that similar specifici-
ties are applied to facilitate comparisons. Regarding
lung function tests it is generally accepted that the
lower limit normal is defined as to result in 95% speci-
ficity. Accordingly the cut off value in the present
study was chosen so that 95% of all measurements
from 6 months post transplantation onward of the 43
stable patients were defined as normal. There appears
to be no doubt in that indexes of ventilation distribu-
tion are in excellent agreement with the BOS diagno-
sis, i e having high sensitivitiy, but that abnormal
values occur to some extent also among those patients
who do not have BOS, resulting in less favorable posi-
tive predictive values.
The ability of various indexes of ventilation distribu-
tion to predict BOS was indicated in an earlier report
[9] and has since been confirmed by others [11,12]
reporting the time delay between reaching the cut off
and the diagnose of BOS. Estenne et al reported that an
increased alveolar slope preceded BOS in 17 of 18 BOS
patients, but this was also obtained in 7 of 39 patients
who did not develop BOS within the course of the study
[12]. Thus the positive predictive value was 71%. The
present study shows that the probability of a single test
result of the N2 slope to precede BOS within the three
years follow up is only 56%, but when combined with
concomitant FEV1 < 90% of the basal value, the
Table 3 Number of normal and abnormal test results divided according to the current diagnostic status among 58
double lung transplant recipients
Dimension Cut off value NoBOS BOS BOS 0-p
Normal Abnormal Normal Abnormal Normal Abnormal
FEV1 % basal < 90 264 28 0 37 0 7
FVC % basal < 90 276 11 8 27 5 1
N2 slope % basal > 299 240 12 12 13 4 3
FEV1 % pred. < 49 279 14 12 24 7 0
FVC % pred. < 52 275 13 24 10 6 0
N2 slope % pred. > 478 234 18 1 24 0 7
Cut off values are based on the 43 patients who did not develop BOS or BOS 0-p and are chosen to give 95% specificity except for FEV < 90% of the basal
value.
Table 4 Operating characteristics of the prevalences shown in a
Dimension Specificity (%) Sensitivity (%) Positive predictive value (%) Negative predictive value (%)
BOS BOS 0-p BOS BOS + BOS 0-p BOS BOS + BOS 0-p
FEV1 % basal 90 100 100 57 61 100 100
FVC % basal 96 77 17 71 72 97 96
N2 slope % basal 95 52 43 52 57 95 94
FEV1 % pred. 95 67 0 63 63 96 94
FVC % pred. 95 29 0 43 43 92 90
N2 slope % pred. 93 96 100 57 63 100 100
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ered clinically useful. A drawback is the relatively low
prevalence of this combination. Considering the moder-
ate regular control scheme in our transplantation unit
compared to previous reports, the analysis based on sin-
gle test results appears suitable but will necessarily
result in more false positive results. Furthermore, as the
number of BOS cases was rather small in the present
study as well as in previous similar studies, the calcu-
lated characteristics are based on small numbers.
Another limitation to our study is the retrospective
study design which is a risk that the results can be more
observational. Preferably, one should apply the N2-test
in a larger patient cohort and in a prospective manner
to ascertain how it would serve as an early predictor of
BOS.
T h ed a t aa v a i l a b l ef o rt h es t u d yw a sar e t r o s p e c t i v e
analysis of patients from 1990 up until 2003. The inten-
tion was to have a stable immunosuppressive protocol
as well as CMV prophylaxis regimen for the studied
cohort and minimize for possible confounding factors.
Since 2003 the regime and prophylaxis have been
altered according to new international guidelines.
The pulmonary function laboratory at our institution
has considerable experience of the N2 test and all tech-
nicians performing the tests were experienced and used
Table 5 Results of FEV1 and the N2 test from 6 to 24 months post transplantation
Definition of
abnormal
Total number of test
results
Total number of abnormal
results
Number of abnormal results
preceding BOS
Predictive value
(%)
FEV1 < 90% basal 299 28 11 39
N2 test > 478% pred. 259 22 12 55
FEV1 + N2
test
Both definitions 259 12 9 75
Results in NoBOS patients and in those preceding the diagnosis of BOS are included
Figure 1 Ratio of FEV1 < 90% basal and N2-test > 478% predicted over time. Figure 1 illustrates the number of occasions over time (n =
12) when the test results of both FEV1 < 90% basal and N2-test > 478% predicted were abnormal. Black bars denote when abnormal values
preceded BOS (n = 9).
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blinded to the status of the patient. Furthermore, the
applied algorithm for the determination of the slope is
robust [16], i.e. the difference of N2 concentration
between the closing point and TLC - 0,825 mL BTPS
divided by the corresponding volume. The chosen cut
off values depend on this algorithm and also on the
applied reference equation [19] since the cut off values
are expressed in percent of predicted normal.
A diagnosis of BOS depends on exclusion of other
possible causes of a decline in FEV1 [23]. In the present
material, the numerous routinely performed clinical
examinations, chest radiographs and surveillance
bronchoscopies with BAL and TBB ensure that possible
confounding factors are reasonably controlled for. The
NoBOS patients, however, defined as not having BOS at
the follow-up examinations, probably contain some
patients who later will develop BOS. This circumstance
may certainly influence the analysis, but presumably
does not influence the comparison of the N2-slope and
BOS 0-p regarding the predictability.
The treatment of BOS has over the years been unsuc-
cessful, but more recently several promising therapeutic
approaches have been proposed [24-26]. An intensified
treatment at an early stage of the disease, i.e.B O S0 - p
might prevent the irreversible functional impairment
which otherwise would occur.
Conclusions
We conclude that a single abnormally steep N2-slope in
combination with a concomitant FEV1 <9 0 %o ft h e
basal value, is clinically useful in predicting BOS. Fol-
low-up protocols of heart-lung and bilateral lung trans-
plant recipients should preferably include lung function
tests sensitive to obstruction of the small peripheral air-
ways, e g single-breath washout tests.
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